Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Complete Genomics is building a facility full of automated sequencing instruments like this one.

Companies are struggling to make it fast, affordable, and profitable to sequence individuals’ genomes–a tall order considering that until late 2008, fewer than 10 human genomes had been sequenced, and those at considerable expense. Four-year-old startup Complete Genomics, based in Mountain View, CA, thinks it has cracked the problem. It demonstrated its technology by sequencing what it claims were more than 50 genomes in 2009. Now it is scaling up its facility to sequence, it says, as many as 5,000 individual genomes in 2010, with 10,000 genomes a year thereafter, at $1,500 to $5,000 each.

The key to the company’s technology is the ability to analyze more than a billion amplified particles of DNA on a single microscope slide. Putting so much information on a single array reduces the number of slides and the amount of expensive reagent required to sequence a genome, and it speeds up digital imaging. Rather than selling its sequencing technology in the form of machines, reagents, and software, as its competitors do, Complete Genomics sells sequencing as a service, taking orders from researchers who FedEx samples to the company–eight genomes minimum, no maximum. “That’s a very easy business to scale up quite rapidly,” says CEO Clifford Reid.

For now, the company is taking advantage of the pent-up demand for sequencing among researchers, who have already placed orders ranging from tens to hundreds of genomes. After the initial research rush passes, Complete Genomics hopes to enter consumer and medical markets. The continuing drop in prices (see “A Moore’s Law for Genetics”) leads some experts to predict that soon the genome of every newborn will be sequenced at birth. That’s more than four million genomes per year in the United States alone. And most oncology researchers believe that sequencing the DNA of a patient’s tumor will one day be the key to effective treatment. Because every cancer seems to have its own set of mutations, its entire genome will be sequenced as if it were a person.

Given the potential demand, Reid is bullish. He says, “We expect to open 10 sequencing centers around the world that, collectively, will have the ability to sequence one million genomes over the next five years.”

0 comments about this story. Start the discussion »

Credit: Jen Siska

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me